AzurRx BioPharma
760 Parkside Avenue
Downstate Biotechnology Incubator, Suite 217
Brooklyn
New York
11226
United States
Tel: 646-699-7855
Website: http://www.azurrx.com/
Email: info@azurrx.com
About AzurRx BioPharma
AzurRx BioPharma, Inc. aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the company’s lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infection. The company is headquartered in Brooklyn, NY, with scientific operations based in Langlade, France.LEADERSHIP:
CEO: Thijs Spoor
CSO: Daniel Dupret
CLINICAL TRIAL:
Please click here for clinical trial information.
100 articles about AzurRx BioPharma
-
AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections
2/9/2021
AzurRx BioPharma, Inc. (NASDAQ: AZRX ), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that it has entered into an agreement with PPD, Inc. (NASDAQ: PPD ), a leading global contract research organization (CRO), for its planned Phase 2 clinic trial
-
AzurRx BioPharma Announces Completion of Enrollment in First Cohort of Phase 2b OPTION 2 Extension Study of MS1819
1/28/2021
AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) diseases, today announced the completion of patient enrollment in the first cohort of the Phase 2b OPTION 2 extension study evaluating immediate-release capsules of MS1819 for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis
-
AzurRx BioPharma Adds Two New Clinical Trial Sites in Europe for Phase 2b OPTION 2 Extension Study of MS1819 Immediate-Release Capsules in Cystic Fibrosis Patients
1/26/2021
AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) diseases, today announced the activation of two additional clinical trial sites in Poland for the extension arm of the Phase 2b OPTION 2 study investigating immediate-release capsules of MS1819 for the treatment of exocrine pancreatic insufficiency (EPI)
-
AzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in Cystic Fibrosis Patients
1/21/2021
AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) diseases, today announced the first two patients have been dosed in the Phase 2b OPTION 2 extension study of MS1819 using immediate release capsules for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.
-
AzurRx BioPharma CEO Issues Letter to Shareholders - Jan 08, 2021
1/8/2021
AzurRx BioPharma, Inc., a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal diseases, issued the following letter to its shareholders and the investment community from James Sapirstein, President and Chief Executive Officer.
-
AzurRx BioPharma to Participate in Biotech Showcase Digital 2021 Conference
1/7/2021
AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the Company will be participating in this year’s Biotech Showcase Digital 2021 conference. James Sapirstein, President & CEO of AzurRx BioPharma, and the Company’s senior management team will be participating in virtual one-on-one meet
-
AzurRx BioPharma to Participate in 10th Annual LifeSci Partners Corporate Access Event
1/5/2021
AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the Company will participate in the 10th Annual LifeSci Partners Corporate Access Event.
-
AzurRx BioPharma Announces Exclusive Worldwide License Agreement with First Wave Bio for Use of Proprietary Niclosamide Formulations to Treat Immune Checkpoint Inhibitor-Associated Colitis and COVID-19 Gastrointestinal Infections
1/4/2021
AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company specializing in the development of non-systemic therapies for gastrointestinal (GI) diseases, today announced that it has signed an exclusive worldwide licensing agreement with First Wave Bio, Inc.
-
AzurRx BioPharma Announces $8.0 Million Offerings
1/4/2021
AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal (GI) diseases, today announced that in conjunction with entering into an exclusive worldwide licensing agreement with First Wave Bio, Inc. (“First Wave”) it has entered into a securities purchase agreement (the “Purchase Agreement”) with a single healthcare-focused institut
-
It was a moderately busy week for clinical trial news, with some important reports coming out about COVID-19 vaccines. Here’s a look.
-
AzurRx BioPharma Announces First Patients Dosed in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
11/30/2020
AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that the first two patients have been dosed in Turkey for its Phase 2 trial evaluating its investigational drug, MS1819,
-
AzurRx BioPharma Requests Protocol Amendment to Phase 2b OPTION 2 Study of MS1819 in Cystic Fibrosis Patients
11/17/2020
AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it will be submitting a protocol amendment request to the U.S. Food and Drug Administrati
-
AzurRx BioPharma Identifies Asymchem as Potential Partner of Choice for MS1819 Phase 3 Clinical Trial Drug Production
11/10/2020
AzurRx BioPharma, Inc. announced that it has signed a binding letter of intent with Asymchem, a leading global contract development and manufacturing service provider, for the development and production of MS1819 for the treatment of exocrine pancreatic insufficiency.
-
AzurRx BioPharma Provides Insight into Drawbacks of Using Porcine Products in Production of Pharmaceuticals and Medicinals, Offers Update on Efforts to Produce Synthetic Alternatives
10/29/2020
AzurRx BioPharma, Inc. ( NASDAQ: AZRX ) (“AzurRx” or the “Company”), a New York-based biopharmaceutical company specializing in the development of therapeutic proteins for the treatment of patients with gastrointestinal disorders, today provides insight on the usage of porcine products in producing pharmaceuticals and medicinals and the inherent downsides associated with this usage, as well as updates regarding its own
-
AzurRx BioPharma Announces Formation of Scientific Advisory Board
10/21/2020
AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced the formation of a Scientific Advisory Board (SAB) including three of the leading global experts in exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.
-
AzurRx BioPharma Activates Additional Clinical Trial Sites in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis
10/14/2020
Two clinical trial sites activated in Turkey, with patient screening initiated Follows activation of six clinical sites in Hungary and dosing of first eight patients Topline data expected in Q2 2021 NEW YORK, Oct. 14, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it has activated two trial sites in
-
AzurRx BioPharma CEO Issues Letter to Shareholders - Oct 07, 2020
10/7/2020
AzurRx BioPharma, Inc., a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, issued the following letter to its shareholders and the investment community from James Sapirstein, President and Chief Executive Officer.
-
AzurRx BioPharma Announces Two Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Conference
9/15/2020
Abstracts to Focus on: Results from Phase 2, Open-Label, Multicenter, 2x2 Cross-Over Trial to Assess Safety and Efficacy of MS1819 in Patients with Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis & Best Enteric Capsule for Targeted Duodenal Delivery of Non-Porcine MS1819 Lipase Enzyme NEW YORK, Sept. 15, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapi
-
AzurRx BioPharma to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference (September 14) and the LD 500 Virtual Conference (September 4)
8/31/2020
AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it will be making company presentations at two upcoming investor conferences: the 2020 H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14th at 4:30 p.m.
-
AzurRx BioPharma Initiates European Arm of Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis
8/17/2020
Three clinical trial sites activated in Poland, with patient screening initiated Follows activation of six clinical sites in the U.S. and dosing of first three patients Topline data expected in Q1 2021